Benefit
Whilst the Conix platform technology is simple in its design, its true strength lies in an ability to deliver drug effectively to the deep lung whilst at the same time reducing upper airway deposition.
The technology is based around patented 'reverse flow cyclone' technology and contains no moving parts or propellants. The Conix technology has demonstrated up to twice the respirable dose compared with market-leading products in back-to-back trials.